Abstract
MicroRNAs are post-transcriptional regulators of gene expression with tissue-specific expression profiles. Dysregulation of microRNAs has been shown to play a role in carcinogenesis. Although progress has been made in the diagnosis and treatment of many cancers, pancreatic cancer remains an intractable public health problem, causing 6.58% of cancer deaths despite making up less than 3% of cancer diagnoses in the United States. No screening, diagnostic or imaging techniques exist with the sensitivity to detect pancreatic cancer in its early, operable stages. Risk factors include numerous inherited syndromes, diabetes mellitus, and hepatitis C virus infection. Here we review the literature regarding dysregulation of microRNA expression in native pancreas, pancreatic ductal adenocarcinoma (the dominant form of pancreatic cancer), and its risk factors to illuminate the biology and progression of this disease. We explore promising evidence for the use of microRNAs as prognostic and diagnostic tools, and discuss emerging reports on microRNA therapeutics.
Keywords: Biomarker, microRNA, pancreatic ductal adenocarcinoma, pancreatic intraepithelial neoplasia, carcinogenesis, malignancy, asymptomatic, papillary, serum, Endocrine.
MicroRNA
Title:No miR Quirk: Dysregulation of microRNAs in Pancreatic Ductal Adenocarcinoma
Volume: 1 Issue: 1
Author(s): Philip Y. Cheung, Anna E. Szafranska-Schwarzbach, Annette M. Schlageter, Bernard F. Andruss and Glen J. Weiss
Affiliation:
Keywords: Biomarker, microRNA, pancreatic ductal adenocarcinoma, pancreatic intraepithelial neoplasia, carcinogenesis, malignancy, asymptomatic, papillary, serum, Endocrine.
Abstract: MicroRNAs are post-transcriptional regulators of gene expression with tissue-specific expression profiles. Dysregulation of microRNAs has been shown to play a role in carcinogenesis. Although progress has been made in the diagnosis and treatment of many cancers, pancreatic cancer remains an intractable public health problem, causing 6.58% of cancer deaths despite making up less than 3% of cancer diagnoses in the United States. No screening, diagnostic or imaging techniques exist with the sensitivity to detect pancreatic cancer in its early, operable stages. Risk factors include numerous inherited syndromes, diabetes mellitus, and hepatitis C virus infection. Here we review the literature regarding dysregulation of microRNA expression in native pancreas, pancreatic ductal adenocarcinoma (the dominant form of pancreatic cancer), and its risk factors to illuminate the biology and progression of this disease. We explore promising evidence for the use of microRNAs as prognostic and diagnostic tools, and discuss emerging reports on microRNA therapeutics.
Export Options
About this article
Cite this article as:
Y. Cheung Philip, E. Szafranska-Schwarzbach Anna, M. Schlageter Annette, F. Andruss Bernard and J. Weiss Glen, No miR Quirk: Dysregulation of microRNAs in Pancreatic Ductal Adenocarcinoma, MicroRNA 2012; 1 (1) . https://dx.doi.org/10.2174/2211536611201010049
DOI https://dx.doi.org/10.2174/2211536611201010049 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
Call for Papers in Thematic Issues
Modulatory Roles of Non-coding RNAs in cancer therapy
This thematic issue aims to elucidate the most recent research on ncRNAs in CRCs and discuss the importance and difficulties that may arise in applying this tool on a regular clinical basis.read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
<i>Prunella vulgaris</i> L: Critical Pharmacological, Expository Traditional
Uses and Extensive Phytochemistry: A Review
Current Drug Discovery Technologies Synthesis and Bioactivity Evaluation of Dipeptidyl Peptidase IV Resistant Glucagon-like Peptide-1 Analogues
Protein & Peptide Letters Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry Current Progress in Stem Cell Research and its Potential for Islet Cell Transplantation
Current Molecular Medicine The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML)
Current Signal Transduction Therapy Autoimmunity in Alzheimers Disease as Evidenced by Plasma Immunoreactivity Against RAGE and Aβ42: Complication of Diabetes
Current Alzheimer Research Stability-Indicating RP-HPLC Method for Determination of Metformin Hydrochloride and Natglinide in Bulk and Tablet Formulations
Current Pharmaceutical Analysis Modulation of Nitric Oxide Pathway by Multiligands/RAGE Axis: A Crossing Point on the Road to Microvascular Complication in Diabetes
Current Enzyme Inhibition Management of Type-1 and Type-2 Diabetes by Insulin Injections in Diabetology Clinics - A Scientific Research Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Basis for the Application of Analytical Models of the Bloch NMR Flow Equations for Functional Magnetic Resonance Imaging (fMRI): A Review
Recent Patents on Medical Imaging Insulin Resistance, Obesity and the Metabolic Syndrome. Is there a Therapeutic Role for Endothelin-1 Antagonists?
Current Vascular Pharmacology Vitamin D Deficiency, Prevalence and Treatment in Neonatal Period
Endocrine, Metabolic & Immune Disorders - Drug Targets Attenuation of Diabetes-induced Cardiac and Subcellular Defects by Sulphur-containing Amino Acids
Current Medicinal Chemistry Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Recent Advances on Detection of Modified Forms of Low-Density Lipoproteins
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Focus on MicroRNAs as Biomarker in Pediatric Diseases
Current Pharmaceutical Design Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Inappropriate Antidopaminergic Drug Use in Parkinson’s Disease Inpatients
Current Drug Therapy A Proposal for a New Classification of Type 1 Diabetes Mellitus Based on Clinical and Immunological Evidence
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy
Current Molecular Medicine